FDA lifts partial hold on Mersana cancer drug trial, but shares

NASDAQ:MRSN   Mersana Therapeutics, Inc
Shares of Cambridge-based Mersana Therapeutics Inc . plunged Monday despite announcing that the FDA would allow it to fully restart a cancer drug trial that was paused in July after one patient died.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.